Search

Author/Creator LORTHOLARY, Alain

1. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial. Issue 4 (April 2021)

Authors:
Guigay, Joël; Aupérin, Anne; Fayette, Jérôme; Saada-Bouzid, Esma; Lafond, Cédrik; Taberna, Miren; Geoffrois, Lionnel; Martin, Laurent; Capitain, Olivier; Cupissol, Didier; Castanie, Hélène; Vansteene, Damien; Schafhausen, Philippe; Johnson, Alison; Even, Caroline; Sire, Christian; Duplomb, Sophie...
Journal:
Lancet oncology
Issue:
Volume 22:Issue 4(2021)
Page Start:
463
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial. Issue 11 (November 2022)

Authors:
Bidard, François-Clément; Hardy-Bessard, Anne-Claire; Dalenc, Florence; Bachelot, Thomas; Pierga, Jean-Yves; de la Motte Rouge, Thibault; Sabatier, Renaud; Dubot, Coraline; Frenel, Jean-Sébastien; Ferrero, Jean Marc; Ladoire, Sylvain; Levy, Christelle; Mouret-Reynier, Marie-Ange; Lortholary, Alai...
Journal:
Lancet oncology
Issue:
Volume 23:Issue 11(2022)
Page Start:
1367
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search